The Claim

In patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH), a novel risk model integrating liver biomarkers with traditional cardiovascular risk factors (LIVER-ASCVD+) improves the prediction of myocardial infarction or stroke events compared to the standard ASCVD Risk Estimator Plus, with an area under the curve (AUC) of 0.68 versus 0.63, and improves mortality prediction with an AUC of 0.63 versus 0.54, enabling better stratification of 10-year cardiovascular risk.

Source: Improving cardiovascular risk prediction in metabolic liver disease with a novel biomarker-enhanced model

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
49score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

In people with MASH, a new risk model that combines liver biomarkers with standard heart disease risk factors predicts heart attacks and strokes more accurately than the current standard model, and also predicts death risk more accurately.

See the scientific wording

In patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH), a novel risk model integrating liver biomarkers with traditional cardiovascular risk factors (LIVER-ASCVD+) improves prediction of myocardial infarction or stroke events, with an area under the curve (AUC) of 0.68, compared to the standard ASCVD Risk Estimator Plus (AUC: 0.63), and improves mortality prediction (AUC: 0.63 vs. 0.54), enabling better stratification of 10-year cardiovascular risk.

Why this might work

Fat buildup and scarring in the liver release signals that make blood vessels stiff, promote clotting, and increase inflammation throughout the body, making heart attacks and strokes more likely.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: Improving cardiovascular risk prediction in metabolic liver disease with a novel biomarker-enhanced model

    In people with severe fatty liver disease, adding liver blood tests to the usual heart risk calculator helps doctors better guess who might have a heart attack or stroke in the next 10 years — and the new calculator works better than the old one.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.